Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC.IOVA · Entity 2090 | Director · Interim CEO & General Counsel | September 08, 2026 | September 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IOVANCE BIOTHERAPEUTICS, INC.
Report date September 08, 2026 · Filed September 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 602,085 |
Reported balance
After 2026-09-08 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-08 · Exercise / conversion · Acquired 15,626 · Balance 602,085 F1: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. |
| Common StockSEC Table I · non-derivative | Direct | 595,447 |
Reported balance
After 2026-09-08 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-09-08 · Tax withholding · Disposed 6,638 · Balance 595,447 F2: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3: Represents common stock remaining after deducting the common stock withheld for taxes. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 93,756 |
Reported balance
After 2026-09-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-08 · Exercise / conversion · Disposed 15,626 · Balance 93,756 F4: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5: The remaining RSUs will vest in equal quarterly installments. F6: Such aggregate number reflects the remainder of such RSUs granted on March 5, 2025, but does not include any other RSUs held by such Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date.
F2: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities.
F3: Represents common stock remaining after deducting the common stock withheld for taxes.
F4: Each RSU represents a contingent right to receive one share of the Issuer's common stock.
F5: The remaining RSUs will vest in equal quarterly installments.
F6: Such aggregate number reflects the remainder of such RSUs granted on March 5, 2025, but does not include any other RSUs held by such Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 08, 2026 Filed Sep 10, 2026 21:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 15,626 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-106752 · tm2625111-3_4seq1.xml · derivative · entry 3 Vogt Frederick G · CIK 0001719678 · Director · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,756 Underlying: Common stock · 15,626 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F6 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 5, 2025, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| September 08, 2026 Filed Sep 10, 2026 21:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 6,638 | $8.70 | $57,750.60 |
DisclosureSEC source: 0001104659-26-106752 · tm2625111-3_4seq1.xml · nonDerivative · entry 2 Vogt Frederick G · CIK 0001719678 · Director · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 595,447 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| September 08, 2026 Filed Sep 10, 2026 21:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 15,626 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-106752 · tm2625111-3_4seq1.xml · nonDerivative · entry 1 Vogt Frederick G · CIK 0001719678 · Director · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 602,085 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 21:02 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 41,669 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-105101 · tm2624648-3_4seq1.xml · derivative · entry 3 Vogt Frederick G · CIK 0001719678 · Director · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,338 Underlying: Common stock · 41,669 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F6 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 1, 2024, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 21:02 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 17,702 | $8.28 | $146,572.56 |
DisclosureSEC source: 0001104659-26-105101 · tm2624648-3_4seq1.xml · nonDerivative · entry 2 Vogt Frederick G · CIK 0001719678 · Director · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 586,459 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 21:02 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 41,669 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-105101 · tm2624648-3_4seq1.xml · nonDerivative · entry 1 Vogt Frederick G · CIK 0001719678 · Director · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 604,161 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| June 05, 2026 Filed Jun 9, 2026 17:03 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 15,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-071899 · tm2617137-4_4seq1.xml · derivative · entry 3 Vogt Frederick G · CIK 0001719678 · Director · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,382 Underlying: Common stock · 15,625 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F6 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 5, 2025, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| June 05, 2026 Filed Jun 9, 2026 17:03 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 6,638 | $4.23 | $28,078.74 |
DisclosureSEC source: 0001104659-26-071899 · tm2617137-4_4seq1.xml · nonDerivative · entry 2 Vogt Frederick G · CIK 0001719678 · Director · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 562,492 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| June 05, 2026 Filed Jun 9, 2026 17:03 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 15,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-071899 · tm2617137-4_4seq1.xml · nonDerivative · entry 1 Vogt Frederick G · CIK 0001719678 · Director · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 569,130 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 21:02 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 41,668 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-070155 · tm2616710-4_4seq1.xml · derivative · entry 3 Vogt Frederick G · CIK 0001719678 · Director · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,007 Underlying: Common stock · 41,668 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F6 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 1, 2024, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 21:02 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 17,701 | $3.96 | $70,095.96 |
DisclosureSEC source: 0001104659-26-070155 · tm2616710-4_4seq1.xml · nonDerivative · entry 2 Vogt Frederick G · CIK 0001719678 · Director · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 553,505 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 21:02 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 41,668 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-070155 · tm2616710-4_4seq1.xml · nonDerivative · entry 1 Vogt Frederick G · CIK 0001719678 · Director · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 571,206 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 21:07 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantRestricted Stock Units · Derivative | 235,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-026457 · tm268453-6_4seq1.xml · derivative · entry 1 Vogt Frederick G · CIK 0001719678 · Director · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 235,000 Underlying: Common stock · 235,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the RSUs shall vest over three years, with (i) one-third of the RSUs vesting on the one-year anniversary of the date of grant and (ii) the remaining RSUs shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant. F2 · derivative.expiration_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the RSUs shall vest over three years, with (i) one-third of the RSUs vesting on the one-year anniversary of the date of grant and (ii) the remaining RSUs shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant. Read SEC document |
| March 05, 2026 Filed Mar 6, 2026 22:02 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 62,493 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-024765 · tm268187-4_4seq1.xml · derivative · entry 3 Vogt Frederick G · CIK 0001719678 · Director · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,007 Underlying: Common stock · 62,493 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F6 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 5, 2025, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| March 05, 2026 Filed Mar 6, 2026 22:02 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 26,755 | $4.58 | $122,537.90 |
DisclosureSEC source: 0001104659-26-024765 · tm268187-4_4seq1.xml · nonDerivative · entry 2 Vogt Frederick G · CIK 0001719678 · Director · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 529,538 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| March 05, 2026 Filed Mar 6, 2026 22:02 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 62,493 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-024765 · tm268187-4_4seq1.xml · nonDerivative · entry 1 Vogt Frederick G · CIK 0001719678 · Director · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 556,293 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 22:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 10,418 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-023539 · tm267902-4_4seq1.xml · derivative · entry 4 Vogt Frederick G · CIK 0001719678 · Director · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 10,418 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F7 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 2, 2023, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 22:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 41,669 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-023539 · tm267902-4_4seq1.xml · derivative · entry 3 Vogt Frederick G · CIK 0001719678 · Director · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 166,675 Underlying: Common stock · 41,669 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F6 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 1, 2024, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 22:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 22,809 | $3.79 | $86,446.11 |
DisclosureSEC source: 0001104659-26-023539 · tm267902-4_4seq1.xml · nonDerivative · entry 2 Vogt Frederick G · CIK 0001719678 · Director · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 493,800 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 22:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 52,087 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-023539 · tm267902-4_4seq1.xml · nonDerivative · entry 1 Vogt Frederick G · CIK 0001719678 · Director · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 516,609 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| December 02, 2025 Filed Dec 3, 2025 22:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 10,417 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-118168 · tm2532666-2_4seq1.xml · derivative · entry 6 Vogt Frederick G · CIK 0001719678 · Director · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,418 Underlying: Common stock · 10,417 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F7 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 2, 2023, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| December 02, 2025 Filed Dec 3, 2025 22:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 4,426 | $2.14 | $9,471.64 |
DisclosureSEC source: 0001104659-25-118168 · tm2532666-2_4seq1.xml · nonDerivative · entry 4 Vogt Frederick G · CIK 0001719678 · Director · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 464,522 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| December 02, 2025 Filed Dec 3, 2025 22:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 10,417 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-118168 · tm2532666-2_4seq1.xml · nonDerivative · entry 3 Vogt Frederick G · CIK 0001719678 · Director · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 468,948 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| December 01, 2025 Filed Dec 3, 2025 22:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 41,669 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-118168 · tm2532666-2_4seq1.xml · derivative · entry 5 Vogt Frederick G · CIK 0001719678 · Director · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 208,344 Underlying: Common stock · 41,669 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F6 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 1, 2024, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| December 01, 2025 Filed Dec 3, 2025 22:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 17,701 | $2.23 | $39,473.23 |
DisclosureSEC source: 0001104659-25-118168 · tm2532666-2_4seq1.xml · nonDerivative · entry 2 Vogt Frederick G · CIK 0001719678 · Director · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 458,531 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| December 01, 2025 Filed Dec 3, 2025 22:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 41,669 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-118168 · tm2532666-2_4seq1.xml · nonDerivative · entry 1 Vogt Frederick G · CIK 0001719678 · Director · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 476,232 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 22:35 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 41,669 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-087549 · tm2525186-4_4seq1.xml · derivative · entry 4 Vogt Frederick G · CIK 0001719678 · Director · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,013 Underlying: Common stock · 41,669 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F7 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 1, 2024, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 22:35 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 10,417 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-087549 · tm2525186-4_4seq1.xml · derivative · entry 3 Vogt Frederick G · CIK 0001719678 · Director · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,385 Underlying: Common stock · 10,417 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F6 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 2, 2023, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 22:35 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 22,127 | $2.19 | $48,458.13 |
DisclosureSEC source: 0001104659-25-087549 · tm2525186-4_4seq1.xml · nonDerivative · entry 2 Vogt Frederick G · CIK 0001719678 · Director · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 434,563 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 22:35 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 52,086 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-087549 · tm2525186-4_4seq1.xml · nonDerivative · entry 1 Vogt Frederick G · CIK 0001719678 · Director · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 456,690 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 20:50 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 41,668 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-056440 · tm2517077-4_4seq1.xml · derivative · entry 4 Vogt Frederick G · CIK 0001719678 · Director · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 291,682 Underlying: Common stock · 41,668 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F7 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 1, 2024, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 20:50 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 10,417 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-056440 · tm2517077-4_4seq1.xml · derivative · entry 3 Vogt Frederick G · CIK 0001719678 · Director · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,252 Underlying: Common stock · 10,417 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F6 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 2, 2023, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 20:50 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 22,127 | $1.76 | $38,943.52 |
DisclosureSEC source: 0001104659-25-056440 · tm2517077-4_4seq1.xml · nonDerivative · entry 2 Vogt Frederick G · CIK 0001719678 · Director · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 404,604 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 20:50 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 52,085 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-056440 · tm2517077-4_4seq1.xml · nonDerivative · entry 1 Vogt Frederick G · CIK 0001719678 · Director · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 426,731 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| May 14, 2025 Filed May 16, 2025 20:05 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | PurchaseCommon Stock | 25,000 | $1.69 | $42,250.00 |
DisclosureSEC source: 0001104659-25-049999 · tm2515393-1_4seq1.xml · nonDerivative · entry 1 Vogt Frederick G · CIK 0001719678 · Director · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 374,646 F1 · shares: Shares were acquired in the open market during a permitted trading window in accordance with the Issuer's Insider Trading Policy. A copy of the Insider Trading Policy is filed as Exhibit 19.1 to the Issuer's Annual Report on Form 10-K for the year ended December 31, 2024. Read SEC document |
| March 05, 2025 Filed Mar 8, 2025 01:06 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantRestricted Stock Units · Derivative | 187,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-021872 · tm258333-10_4seq1.xml · derivative · entry 1 Vogt Frederick G · CIK 0001719678 · Director · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 187,500 Underlying: Common stock · 187,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the RSUs shall vest over three years, with (i) one-third of the RSUs vesting on the one-year anniversary of the date of grant and (ii) the remaining RSUs shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant. F2 · derivative.expiration_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the RSUs shall vest over three years, with (i) one-third of the RSUs vesting on the one-year anniversary of the date of grant and (ii) the remaining RSUs shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 01:32 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 213,525 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-021057 · tm258333-3_4seq1.xml · derivative · entry 4 Vogt Frederick G · CIK 0001719678 · Director · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 333,350 Underlying: Common stock · 213,525 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F7 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 1, 2024, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 01:32 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 10,418 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-021057 · tm258333-3_4seq1.xml · derivative · entry 3 Vogt Frederick G · CIK 0001719678 · Director · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,669 Underlying: Common stock · 10,418 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F6 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 2, 2023, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 01:32 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 95,413 | $4.04 | $385,468.52 |
DisclosureSEC source: 0001104659-25-021057 · tm258333-3_4seq1.xml · nonDerivative · entry 2 Vogt Frederick G · CIK 0001719678 · Director · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 349,646 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 01:32 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 223,943 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-021057 · tm258333-3_4seq1.xml · nonDerivative · entry 1 Vogt Frederick G · CIK 0001719678 · Director · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 445,059 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| January 14, 2025 Filed Jan 16, 2025 23:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 20,835 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-004205 · tm253469-3_4seq1.xml · derivative · entry 3 Vogt Frederick G · CIK 0001719678 · Director · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 20,835 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F6 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on January 14, 2022, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| January 14, 2025 Filed Jan 16, 2025 23:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 9,955 | $5.89 | $58,634.95 |
DisclosureSEC source: 0001104659-25-004205 · tm253469-3_4seq1.xml · nonDerivative · entry 2 Vogt Frederick G · CIK 0001719678 · Director · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 221,116 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| January 14, 2025 Filed Jan 16, 2025 23:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 20,835 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-004205 · tm253469-3_4seq1.xml · nonDerivative · entry 1 Vogt Frederick G · CIK 0001719678 · Director · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 231,071 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 21:31 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 10,417 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-125547 · tm2430163-3_4seq1.xml · derivative · entry 3 Vogt Frederick G · CIK 0001719678 · Director · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,087 Underlying: Common stock · 10,417 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F6 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 2, 2023, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 21:31 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 4,426 | $9.07 | $40,143.82 |
DisclosureSEC source: 0001104659-24-125547 · tm2430163-3_4seq1.xml · nonDerivative · entry 2 Vogt Frederick G · CIK 0001719678 · Director · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 210,236 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 21:31 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 10,417 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-125547 · tm2430163-3_4seq1.xml · nonDerivative · entry 1 Vogt Frederick G · CIK 0001719678 · Director · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 214,662 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| October 14, 2024 Filed Oct 16, 2024 22:33 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 20,834 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-109279 · tm2426276-3_4seq1.xml · derivative · entry 3 Vogt Frederick G · CIK 0001719678 · Director · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,835 Underlying: Common stock · 20,834 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F6 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on January 14, 2022, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| October 14, 2024 Filed Oct 16, 2024 22:33 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 8,851 | $9.77 | $86,474.27 |
DisclosureSEC source: 0001104659-24-109279 · tm2426276-3_4seq1.xml · nonDerivative · entry 2 Vogt Frederick G · CIK 0001719678 · Director · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 204,245 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| October 14, 2024 Filed Oct 16, 2024 22:33 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 20,834 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-109279 · tm2426276-3_4seq1.xml · nonDerivative · entry 1 Vogt Frederick G · CIK 0001719678 · Director · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 213,096 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 23:56 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 46,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-097491 · tm2423453-4_4seq1.xml · derivative · entry 6 Vogt Frederick G · CIK 0001719678 · Director · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,875 Underlying: Common Stock · 46,875 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F7 · derivative.exercise_date: The remaining RSUs will vest on the one-year anniversary of the initial grant date, as provided in footnote 8. F7 · derivative.expiration_date: The remaining RSUs will vest on the one-year anniversary of the initial grant date, as provided in footnote 8. F8 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 1, 2024, but does not include any other RSUs held by such Reporting Person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.